Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$3.78
+7.1%
$3.01
$1.60
$16.55
$280.58M1.181.08 million shs1.19 million shs
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
$13.05
+0.4%
$12.95
$11.06
$32.66
$1.01B1.15966,491 shs673,072 shs
Inari Medical, Inc. stock logo
NARI
Inari Medical
$79.97
$79.97
$39.76
$79.99
$4.68B1.021.45 million shsN/A
NovoCure Limited stock logo
NVCR
NovoCure
$18.19
+3.9%
$17.66
$14.17
$34.13
$1.95B0.721.13 million shs926,433 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
+7.08%+11.50%+17.03%+103.23%-64.37%
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
+0.38%-3.48%-5.98%-25.09%-54.97%
Inari Medical, Inc. stock logo
NARI
Inari Medical
0.00%0.00%0.00%0.00%+56.37%
NovoCure Limited stock logo
NVCR
NovoCure
+3.88%+1.73%+7.63%+13.12%+8.21%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
1.0784 of 5 stars
3.61.00.00.00.00.80.0
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
4.0586 of 5 stars
2.91.00.04.01.31.72.5
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/AN/AN/AN/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
3.5963 of 5 stars
3.41.00.04.51.91.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.18
Buy$12.56232.16% Upside
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
1.78
Reduce$18.6342.72% Upside
Inari Medical, Inc. stock logo
NARI
Inari Medical
2.14
Hold$69.22-13.44% Downside
NovoCure Limited stock logo
NVCR
NovoCure
2.71
Moderate Buy$32.4378.28% Upside

Current Analyst Ratings Breakdown

Latest CATX, NARI, IART, and NVCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
NovoCure Limited stock logo
NVCR
NovoCure
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/27/2025
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$34.00
6/23/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $12.00
6/23/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00
6/3/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.00
5/14/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
5/13/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
5/9/2025
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$35.00 ➝ $25.00
5/6/2025
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $13.00
5/6/2025
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$24.00 ➝ $12.00
4/23/2025
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/A$2.67 per shareN/A
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
$1.61B0.63$4.47 per share2.92$20.03 per share0.65
Inari Medical, Inc. stock logo
NARI
Inari Medical
$493.63M9.48$0.09 per share906.95$8.07 per share9.91
NovoCure Limited stock logo
NVCR
NovoCure
$621.71M3.26N/AN/A$3.33 per share5.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
-$6.94M-$0.38N/A5.220.73-1.78%12.12%4.58%8/4/2025 (Estimated)
Inari Medical, Inc. stock logo
NARI
Inari Medical
-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/A
NovoCure Limited stock logo
NVCR
NovoCure
-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)

Latest CATX, NARI, IART, and NVCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
$0.43N/AN/AN/AN/AN/A
7/24/2025Q2 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.40N/AN/AN/A$153.87 millionN/A
5/5/2025Q1 2025
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
$0.43$0.41-$0.02-$0.33$381.17 million$382.65 million
4/24/2025Q1 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/AN/A
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
N/AN/AN/AN/AN/A
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/A
9.60
9.60
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
0.81
1.21
0.72
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/A
1.77
1.40
NovoCure Limited stock logo
NVCR
NovoCure
0.27
1.47
1.41

Institutional Ownership

CompanyInstitutional Ownership
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
54.66%
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
84.78%
Inari Medical, Inc. stock logo
NARI
Inari Medical
90.98%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%

Insider Ownership

CompanyInsider Ownership
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.72%
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
3.54%
Inari Medical, Inc. stock logo
NARI
Inari Medical
10.60%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
7074.23 million65.21 millionOptionable
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
4,39677.71 million74.96 millionOptionable
Inari Medical, Inc. stock logo
NARI
Inari Medical
80058.54 million52.34 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,488111.49 million105.33 millionOptionable

Recent News About These Companies

Brokerages Set NovoCure Limited (NASDAQ:NVCR) PT at $32.83
What Makes NovoCure (NVCR) a New Buy Stock
NovoCure (NASDAQ:NVCR) Trading Up 6.5% - Here's Why

New MarketBeat Followers Over Time

Media Sentiment Over Time

Perspective Therapeutics stock logo

Perspective Therapeutics NYSE:CATX

$3.78 +0.25 (+7.08%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$3.71 -0.07 (-1.88%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Integra LifeSciences stock logo

Integra LifeSciences NASDAQ:IART

$13.05 +0.05 (+0.38%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$13.04 -0.01 (-0.07%)
As of 05:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Inari Medical stock logo

Inari Medical NASDAQ:NARI

$79.97 0.00 (0.00%)
As of 02/19/2025

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$18.19 +0.68 (+3.88%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$18.20 +0.01 (+0.08%)
As of 07/9/2025 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.